Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
Public ClinicalTrials.gov record NCT00615563. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective was to examine clinicians' use of HIV drug resistance testing in treatment experienced patients currently failing a PI based HAART regimen.
Study identification
- NCT ID
- NCT00615563
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 246 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2007 (Type not available)
- Primary completion
- Jan 2008 (Actual)
- Completion
- Jan 2008 (Type not available)
- Last update posted
- Nov 21, 2013
2007 – 2008
United States locations
- U.S. sites
- 34
- U.S. states
- 15
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Bakersfield | California | 93301 | — |
| Boehringer Ingelheim Investigational Site | Beverly Hills | California | 90211 | — |
| Boehringer Ingelheim Investigational Site | Fountain Valley | California | 92708 | — |
| Boehringer Ingelheim Investigational Site | Los Angeles | California | 90028 | — |
| Boehringer Ingelheim Investigational Site | Los Angeles | California | 90069 | — |
| Boehringer Ingelheim Investigational Site | Newport Beach | California | 92663 | — |
| Boehringer Ingelheim Investigational Site | Oakland | California | 94609 | — |
| Boehringer Ingelheim Investigational Site | Stanford | California | 94305-5107 | — |
| Boehringer Ingelheim Investigational Site | Daytona Beach | Florida | 32117 | — |
| Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | 33316 | — |
| Boehringer Ingelheim Investigational Site | Miami | Florida | 33133 | — |
| Boehringer Ingelheim Investigational Site | Miami | Florida | 33137 | — |
| Boehringer Ingelheim Investigational Site | North Palm Beach | Florida | 33408 | — |
| Boehringer Ingelheim Investigational Site | Pensacola | Florida | 32504 | — |
| Boehringer Ingelheim Investigational Site | Chicago | Illinois | 60613 | — |
| Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | 70121 | — |
| Boehringer Ingelheim Investigational Site | Baltimore | Maryland | 21201 | — |
| Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | 01107 | — |
| Boehringer Ingelheim Investigational Site | Berkley | Michigan | 48072 | — |
| Boehringer Ingelheim Investigational Site | St Louis | Missouri | 63139 | — |
| Boehringer Ingelheim Investigational Site | Camden | New Jersey | 08103 | — |
| Boehringer Ingelheim Investigational Site | Newark | New Jersey | 07102 | — |
| Boehringer Ingelheim Investigational Site | Newark | New Jersey | 07103 | — |
| Boehringer Ingelheim Investigational Site | Voorhees Township | New Jersey | 08043 | — |
| Boehringer Ingelheim Investigational Site | Rochester | New York | 14604 | — |
| Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | 28209 | — |
| Boehringer Ingelheim Investigational Site | Huntersville | North Carolina | 28078 | — |
| Boehringer Ingelheim Investigational Site | Akron | Ohio | 44304 | — |
| Boehringer Ingelheim Investigational Site | Portland | Oregon | 97209 | — |
| Boehringer Ingelheim Investigational Site | Dallas | Texas | 75246 | — |
| Boehringer Ingelheim Investigational Site | Fort Worth | Texas | 76104 | — |
| Boehringer Ingelheim Investigational Site | Houston | Texas | 77004 | — |
| Boehringer Ingelheim Investigational Site | Hampton | Virginia | 23666 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00615563, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2013 · Synced Oct 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00615563 live on ClinicalTrials.gov.